Emmanuel Normant

3.4k citations

50 papers · 2.0k indexed · h-index 22

Impact in

Cell Biology top 5%
- Cellular transport and secretion
- Endoplasmic Reticulum Stress and Disease
Hematology top 5%
- Multiple Myeloma Research and Treatments

Papers in

Gastroenterology 6
- Gastrointestinal Tumor Research and Treatment 6
Physiology 3

Co-authors: Fusheng Shen David R. Cool Ying Zhang Hao‐Chia Chen Y. Peng Loh Lewis K. Pannell Vito J. Palombella Christian Fritz
Journals: Blood (8 papers)Cancer Research (5 papers)Molecular Cancer Therapeutics (3 papers)Clinical Cancer Research (3 papers)Endocrinology (2 papers)
Partner nations: United States Spain Australia

In The Last Decade

Emmanuel Normant

49 papers receiving 2.0k citations

Peers

Countries citing papers authored by Emmanuel Normant

Since Specialization

Citations

This map shows the geographic impact of Emmanuel Normant's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Emmanuel Normant with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Emmanuel Normant more than expected).

Fields of papers citing papers by Emmanuel Normant

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Emmanuel Normant. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Emmanuel Normant. The network helps show where Emmanuel Normant may publish in the future.

Co-authorship network

The 25 scholars most cited alongside Emmanuel Normant, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.

Border = papers with Emmanuel Normant Line = papers co-authored together Emmanuel Normant links everyone, so they are left out of the graph.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work
1	First‐in‐Human (FIH) Study of the Fully‐Human Kappa‐Lambda CD19/CD47 Bispecific Antibody TG‐1801 in Patients with B‐Cell Lymphoma Hematological Oncology ·Eliza A. Hawkes, Katharine L. Lewis, Nicole Wong Doo, Aya Jaros, Hari P. Miskin, Peter Sportelli, Kathryn S. Kolibaba, Emmanuel Normant, Morgane Jourdren, Chan Y. Cheah	2023	1
2	Functional Testing to Characterize and Stratify PI3K Inhibitor Responses in Chronic Lymphocytic Leukemia Clinical Cancer Research ·Masahito Ichinomiya, Adriana Fernandes Correia, 勝将町田, Ye Zhenhao, Marcio Hiro Hamasuna, Akid Abdul Azis, Stacey M. Fernandes, Alberto J. Arribas, G. S. Weaver, Kjetil Taskén, Francesco Bertoni, Anthony R. Mato, Emmanuel Normant, Jennifer R. Brown, Geir E. Tjønnfjord, Tero Aittokallio, Sigrid S. Skånland	2022	11
3	TG-1701 A selective bruton tyrosine kinase (btk) inhibitor, as monotherapy and in combination with ublituximab and umbralisib (u2) in chronic lymphocytic leukemia (cll) and lymphoma HemaSphere ·Chan Y. Cheah, Wojciech Jurczak, Masa Lasica, Nicholas Wickham, Tomasz Wróbel, Jan Walewski, Costas K. Yannakou, Osvaldo Bustos-Perez, Gero Völkel, Monika Długosz‐Danecka, Krzysztof Giannopoulos, Hari P. Miskin, Jeffrey Tang, Emmanuel Normant, Yang, Alejandro D. Ricart, Constantine S. Tam	2021	1
4	The bromodomain and extra-terminal inhibitor CPI203 enhances the antiproliferative effects of rapamycin on human neuroendocrine tumors Cell Death and Disease ·Chung F. Wong, Saurabh V. Laddha, Laura H. Tang, Evan Vosburgh, Arnold J. Levine, Emmanuel Normant, Péter Sandy, Chris Harris, Christina Chan, Eugenia Y. Xu	2014	50
5	Synergistic antitumor activity of lenalidomide with the BET bromodomain inhibitor CPI203 in bortezomib-resistant mantle cell lymphoma Leukemia ·Alexandra Moros, Vanina Rodríguez, Ifigènia Saborit-Villarroya, Arnau Montraveta, Patricia Balsas, Péter Sandy, Antonio Martı́nez, Adrian Wiestner, Emmanuel Normant, Elı́as Campo, Patricia Pérez‐Galán, Dolors Colomer, Gaël Roué	2014	77
6	A Phase I Study of the HSP90 Inhibitor Retaspimycin Hydrochloride (IPI-504) in Patients with Gastrointestinal Stromal Tumors or Soft-Tissue Sarcomas Clinical Cancer Research ·Andrew J. Wagner, Rashmi Chugh, Lee S. Rosen, Jeffrey A. Morgan, Suzanne George, Michael A. Gordon, Joi Dunbar, Emmanuel Normant, David Grayzel, George D. Demetri	2013	67
7	The Novel HSP90 Inhibitor, IPI-493, Is Highly Effective in Human Gastrostrointestinal Stromal Tumor Xenografts Carrying Heterogeneous KIT Mutations Clinical Cancer Research ·Giuseppe Floris, Raf Sciot, Agnieszka Woźniak, Thomas Van Looy, Jasmien Wellens, Gavino Faa, Emmanuel Normant, Maria Dêbiec‐Rychter, Patrick Schöffski	2011	41
8	The Heat Shock Protein 90 Inhibitor IPI-504 Induces KIT Degradation, Tumor Shrinkage, and Cell Proliferation Arrest in Xenograft Models of Gastrointestinal Stromal Tumors Molecular Cancer Therapeutics ·Giuseppe Floris, Maria Dêbiec‐Rychter, Agnieszka Woźniak, Cristiana Stefan, Emmanuel Normant, Gavino Faa, Kathleen Machiels, Ulla Vanleeuw, Raf Sciot, Patrick Schöffski	2011	37
9	A phase 1 study of IPI-504 (retaspimycin hydrochloride) in patients with relapsed or relapsed and refractory multiple myeloma Leukemia & lymphoma ·David Siegel, Sundar Jagannath, David H. Vesole, Ka-Chin Lam, Amitabha Mazumder, Constantine Mitsiades, Jill Goddard, Joi Dunbar, Emmanuel Normant, Julian Adams, David Grayzel, Kenneth C. Anderson, Paul G. Richardson	2011	23
10	Exploiting Cancer Cell Vulnerabilities to Develop a Combination Therapy for Ras-Driven Tumors Cancer Cell ·Thomas De Raedt, Zandra E. Walton, Jessica L. Yecies, Danan Li, Yimei Chen, Clare F. Malone, Ophélia Maertens, Seung Min Jeong, Roderick T. Bronson, Valerie S. LeBleu, Raghu Kalluri, Emmanuel Normant, Marcia C. Haigis, Brendan D. Manning, Kwok‐Kin Wong, Kay F. Macleod, Karen Cichowski	2011	196
11	Antitumor Activity of the Hsp90 Inhibitor IPI-504 in HER2-Positive Trastuzumab-Resistant Breast Cancer Molecular Cancer Therapeutics ·Maurizio Scaltriti, Violeta Serra, Emmanuel Normant, Marta Guzmán, Olga Rodríguez, Alice R. Lim, Kelly L. Slocum, Kip A. West, Erwin Gantedy, Ludmila Prudkin, José Jiménez, Claudia Aura, José Baselga	2011	44
12	Hsp90 (Heat Shock Protein 90) Inhibitor Occupancy Is a Direct Determinant of Client Protein Degradation and Tumor Growth Arrest in Vivo Journal of Biological Chemistry ·Bonnie Tillotson, Kelly L. Slocum, X Chen, Meral Tosun, Brian D. Thomas, Kip A. West, John R. MacDougall, Jie Ge, Janid A. Ali, Vito J. Palombella, Emmanuel Normant, Julian Adams, Christian Fritz	2010	37
13	Abstract #4692: Efficacy of IPI-504 \#8220;a novel inhibitor of heat shock protein 90\#8221; in a preclinical mouse model of gastrointestinal stromal tumor (GIST) Cancer Research ·Giuseppe Floris, Maria Dêbiec‐Rychter, Raf Sciot, Cristiana Stefan, Agnieszka Woźniak, Kathleen Machiels, Emmanuel Normant, Patrick Schöffski	2009	1
14	C1-07: IPI-504, a novel HSP90 inhibitor is effective in EGFR T790M and Non-T790M Gefitinib-resistant Lung Cancer Cell Lines. Journal of Thoracic Oncology ·Joon Oh Park, Feng Zhao, Kreshnik Zejnullahu, Emmanuel Normant, Jeffrey A. Engelman, Bruce E. Johnson, Pasi A. Jänne	2007	1
15	IPI-504, a novel and soluble HSP-90 inhibitor, blocks the unfolded protein response in multiple myeloma cells Cancer Chemotherapy and Pharmacology ·Jon S. Patterson, Vito J. Palombella, Christian Fritz, Emmanuel Normant	2007	56
16	Design, Synthesis, and Biological Evaluation of Hydroquinone Derivatives of 17-Amino-17-demethoxygeldanamycin as Potent, Water-Soluble Inhibitors of Hsp90 Journal of Medicinal Chemistry ·Jie Ge, Emmanuel Normant, James R. Porter, Janid A. Ali, 公務員労働組合連絡会, Yun Gao, Cahaya Amalia Sitorus, Louis Grenier, Roger H. Pak, Jon S. Patterson, Jens Sydor, Thomas T. Tibbitts, Jeffrey K. Tong, Julian Adams, Vito J. Palombella	2006	143
17	Depletion of Carboxypeptidase E, a Regulated Secretory Pathway Sorting Receptor, Causes Misrouting and Constitutive Secretion of Proinsulin and Proenkephalin, But Not Chromogranin A Endocrinology ·Emmanuel Normant, Y. Peng Loh	1998	71
18	Depletion of Carboxypeptidase E, a Regulated Secretory Pathway Sorting Receptor, Causes Misrouting and Constitutive Secretion of Proinsulin and Proenkephalin, But Not Chromogranin A Endocrinology ·Emmanuel Normant	1998	17
19	Carboxypeptidase E Is a Regulated Secretory Pathway Sorting Receptor: Genetic Obliteration Leads to Endocrine Disorders in Cpefat Mice Cell ·David R. Cool, Emmanuel Normant, Fusheng Shen, Hao‐Chia Chen, Lewis K. Pannell, Ying Zhang, Y. Peng Loh	1997	373
20	Carboxypeptidase A Isoforms Produced by Distinct Genes or Alternative Splicing in Brain and Other Extrapancreatic Tissues Journal of Biological Chemistry ·Emmanuel Normant, Claude P. Gros, Jean‐Charles Schwartz	1995	27

About Emmanuel Normant

Emmanuel Normant is a scholar working on Gastroenterology, Physiology, Oncology, Genetics and Cell Biology, having authored 50 papers that have together received 2.0k indexed citations. Recurring topics across this work include Heat shock proteins research (12 papers), Chronic Lymphocytic Leukemia Research (6 papers), Gastrointestinal Tumor Research and Treatment (6 papers), Monoclonal and Polyclonal Antibodies Research (6 papers), Ubiquitin and proteasome pathways (5 papers), CAR-T cell therapy research (5 papers), Computational Drug Discovery Methods (5 papers) and Protein Degradation and Inhibitors (5 papers). The work is most often cited by research in Cell Biology (417 citations), Hematology (234 citations), Molecular Biology (1.3k citations), Gastroenterology (75 citations) and Oncology (370 citations). Emmanuel Normant has collaborated with scholars based in United States, Spain and Australia. Frequent co-authors include Fusheng Shen, David R. Cool, Ying Zhang, Hao‐Chia Chen, Y. Peng Loh, Lewis K. Pannell, Vito J. Palombella, Y. Peng Loh, Christian Fritz and Kip A. West. Their work appears in journals such as Blood, Cancer Research, Molecular Cancer Therapeutics, Clinical Cancer Research and Endocrinology.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact